Giá hiện tại
Giá mục tiêu
Đánh giá của nhà phân tích
7 xếp hạng: Mua
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
| Metric (B) | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.43 | $-0.30 | $-0.30 | $-0.39 | $-0.36 | $-0.35 | $-0.35 | $-1.63 | $-0.48 | $-2.02 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | |
| +0.0% | +4.7% | +0.0% | -10.4% | +3.3% | +0.0% | +0.0% | +9.1% | -5.8% | -7.6% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NNutriband... | NTRB | $74.15M | — | 13.58 | — | -435.60% | -100.80% | -29.70% |
| 2. | UUnicycive... | UNCY | $97.25M | — | 1.86 | — | — | -101.10% | — |
| 3. | TTenaya The... | TNYA | $79.59M | — | 1.43 | — | -2,657.00% | -148.20% | — |
| 4. | PPMV Pharma... | PMVP | $95.93M | — | 1.68 | — | — | -99.40% | — |
| 5. | CCognition... | CGTX | $64.65M | — | 2.21 | — | — | -48.60% | — |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0.26 | 0.16 | 3.56 | 3.96 | 251.15 | 0.24 | 0.23 |
COGS | 1.94 | 5.21 | 0.01 | 0.01 | -5.2 | 0 | 0 | 0 |
Gross Profit | -1.94 | -4.96 | 0.16 | 3.56 | 9.16 | 0 | 0.24 | 0.23 |
Gross Profit % | -99154.1% | -1921.87% | 95.82% | 99.81% | 231.32% | - | 100% | 100% |
| 2.14 | 2.72 | 6.57 | 5.47 | 13.42 | 7,891.36 | 7.29 | 11.18 | |
EBIT | -4.08 | -7.68 | -6.41 | -1.92 | -4.26 | -7,640.22 | -7.05 | -10.95 |
OPM % | -209031.45% | -2976.89% | -3920.47% | -53.78% | -107.51% | -3042.13% | -2891.13% | -4676.21% |
Non-Operating Income | 0.44 | 0.37 | 0.32 | -0.2 | -1.45 | 433.23 | 0.41 | 0.33 |
PBT | -3.64 | -7.31 | -6.09 | -2.12 | -5.71 | -7,206.99 | -6.64 | -10.62 |
Income Tax | -0.72 | 720.32 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | 19.81% | -9858.32% | - | - | -0.05% | - | - | - |
Net Income | -2.92 | -7.31 | -6.09 | -2.12 | -5.71 | -7,206.99 | -6.64 | -10.62 |
NPM % | -149373.77% | -2833.35% | -3725.17% | -59.36% | -144.16% | -2869.63% | -2723.44% | -4534.9% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 6 | 3.55 | 7.95 |
COGS | 0 | 0.02 | 4.41 | 5.5 | 11.87 | 0.03 |
Gross Profit | 0 | -0.02 | -4.41 | 0.5 | -8.31 | 7.92 |
Gross Profit % | - | - | - | 8.34% | -233.86% | 99.66% |
| 1.04 | 4.87 | 5.4 | 8.4 | 8.94 | 28.18 | |
EBIT | -1.04 | -4.87 | -9.81 | -7.9 | -17.25 | -20.27 |
OPM % | - | - | - | -131.67% | -485.35% | -255.05% |
Non-Operating Income | 0 | -0.02 | -2.43 | 0.64 | 1.65 | -0.96 |
PBT | -1.1 | -4.89 | -12.24 | -7.26 | -15.6 | -21.22 |
Income Tax | -0 | -0.02 | 2.43 | 0.72 | -0.72 | 0 |
Tax Rate % | 0.06% | 0.44% | -19.87% | -9.96% | 4.62% | -0.01% |
Net Income | -1.1 | -4.89 | -12.24 | -7.99 | -14.88 | -21.23 |
NPM % | - | - | - | -133.08% | -418.7% | -267.14% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| 8.72 | 4.34 | 5.93 | 32.63 | 38.34 | 46.82 | |
| 0 | 0 | 0 | 0 | 38,301.42 | 0 | |
| 0 | 0.12 | 0.09 | 0 | 0 | 0 | |
| 0.03 | 0.24 | 1.25 | 8.57 | 5.97 | 3.12 | |
| 0 | 0.09 | 1.12 | 0.07 | -38,301.38 | 0.01 | |
Total Assets | 8.75 | 4.79 | 8.4 | 41.26 | 44.35 | 49.95 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 8.3 | 3.64 | -8.39 | 35.63 | 39.58 | 43.03 | |
| 0 | 0 | 12.97 | 0.72 | 0 | 0 | |
| 0 | 1.15 | 3.82 | 3.41 | 2.98 | 4.67 | |
| 0.45 | 0 | 0 | 1.5 | 1.79 | 2.25 | |
Total Liabilities | 8.75 | 4.79 | 8.4 | 41.26 | 44.35 | 49.95 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| -0.39 | -3.9 | -7.24 | -11.19 | -10.29 | -10.74 | |
| -0.14 | -0.14 | -0.53 | -0.54 | -0.03 | -1.16 | |
| 9.11 | -0.34 | 9.36 | 38.43 | 16.03 | 20.39 | |
Net CFNet Cash Flow | 8.58 | -4.38 | 1.59 | 26.69 | 5.71 | 8.48 |
FCFFree Cash Flow | -0.39 | -4.04 | -7.24 | -11.19 | -10.29 | -10.74 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| - | -81.9% | 515.6% | -58.6% | -39.6% | -51.4% | |
| - | - | -1.54 | 0.02 | - | - | |
| 19.57 | 3.99 | 1.88 | 8.15 | 11.59 | 8.50 | |
| - | 0.00 | 0.00 | 0.24 | 0.08 | 0.17 | |
Cash Conversion | 0.36 | 0.80 | 0.59 | 1.40 | 0.69 | 0.51 |
Payout Ratio | - | - | - | - | - | - |
| - | - | - | - | -40.8% | 123.6% | |
| -0.42 | -1.89 | -4.73 | -0.72 | -0.91 | -1.30 | |
| - | - | -0.99 | -9.42 | -6.72 | -4.13 | |
| 3.00 | 3.00 | 2.00 | 4.00 | 3.00 | 4.00 | |
| - | - | - | - | -4.35 | -5.51 | |
| 0.00 | 0.00 | - | 33.33 | 0.00 | 50.00 | |
| - | - | - | -1.3% | -4.2% | -2.7% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Coya Therapeutics Inc, theo hồ sơ SEC
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 12.73% | 7.19% | 1.22% | 1.22% | 1.11% | 0.28% | 0.21% | 0.21% | 0.00 | |
| 0.14% | 0.46% | 0.33% | 0.26% | 0.53% | 1.86% | 1.59% | 2.10% | +0.51 | |
| 19.71% | 26.11% | 27.55% | 26.64% | 22.22% | 31.98% | 32.97% | 31.05% | -1.93 | |
Govt.Government & pensions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Public | 67.43% | 66.25% | 70.90% | 71.89% | 76.14% | 65.87% | 65.23% | 66.64% | +1.42 |
No. of institutional holders | 19 | 26 | 26 | 33 | 35 | 58 | 56 | 54 | -2 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Holding company | DE | 1,651,440 | 9.90% | SC 13G/A · 14 Feb 2025 | |
| Corporation | NJ | 2,272,727 | 9.70% | SC 13G · 12 Mar 2026 | |
| Holding company | X1 | 764,679 | 3.30% | SC 13G/A · 27 Jul 2026 | |
| Investment adviser | PA | 899,140 | 4.29% | SC 13G/A · 30 Jan 2026 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 30 Oct 2026 | 1,410,974 | +12.4% | 6.01% | 11.89 | |
| 15 Oct 2026 | 1,254,876 | +5.3% | 5.35% | 8.61 | |
| 30 Sep 2026 | 1,191,391 | +0.3% | 5.08% | 7.02 | |
| 15 Sep 2026 | 1,187,873 | +9.4% | 5.06% | 10.24 | |
| 31 Aug 2026 | 1,085,717 | +2.7% | 4.63% | 11.51 | |
| 14 Aug 2026 | 1,057,492 | -1.4% | 4.51% | 7.83 | |
| 31 Jul 2026 | 1,072,865 | +2.3% | 4.57% | 5.18 | |
| 15 Jul 2026 | 1,048,435 | +14.6% | 4.47% | 3.51 | |
| 30 Jun 2026 | 914,908 | -7.6% | 3.90% | 3.73 | |
| 15 Jun 2026 | 990,227 | +7.7% | 4.22% | 5.81 | |
| 29 May 2026 | 919,673 | +12.4% | 3.92% | 8.84 | |
| 15 May 2026 | 818,097 | -0.9% | 3.49% | 4.03 | |
| 30 Apr 2026 | 825,568 | +6.9% | 3.52% | 5.68 | |
| 15 Apr 2026 | 771,973 | -12.5% | 3.29% | 4.92 | |
| 31 Mar 2026 | 882,759 | +6.1% | 3.76% | 5.66 | |
| 13 Mar 2026 | 832,386 | -1.4% | 3.55% | 7.19 | |
| 27 Feb 2026 | 843,949 | +0.2% | 3.60% | 8.91 | |
| 13 Feb 2026 | 842,458 | -4.3% | 3.59% | 5.93 | |
| 30 Jan 2026 | 880,164 | +4.2% | 3.75% | 3.35 | |
| 15 Jan 2026 | 844,387 | +26.8% | 3.60% | 2.08 | |
| 31 Dec 2025 | 665,697 | +29.3% | 2.84% | 3.26 | |
| 15 Dec 2025 | 514,930 | +8.1% | 2.20% | 2.65 | |
| 28 Nov 2025 | 476,287 | +22.9% | 2.03% | 2.31 | |
| 14 Nov 2025 | 387,632 | +14.5% | 1.65% | 2.52 |
FINRA consolidated short interest, reported twice a month for every US listing.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Coya Therapeutics Inc
What recent news says about Coya Therapeutics Inc, scored for sentiment.